Notice 11 Apr 2025 healthcare, grant opportunities, research, regulatory compliance, nih, infectious diseases

🧪NIH Notice of Closed Meeting for Grant Review in Health Sector

The Department of Health and Human Services announces a closed meeting by the National Institute of Allergy and Infectious Diseases to evaluate grant applications. The session, scheduled for May 2025, emphasizes confidentiality of discussions regarding trade secrets and personal information. This review is aimed at advancing research on anti-infective and immune disease therapeutics.

Learn More
Notice 11 Apr 2025 healthcare, social security, low-income assistance, business regulation, wage reporting, compliance

💼New Social Security Matching Program

In accordance with the provisions of the Privacy Act, as amended, this notice announces a new matching program with the United Stated Department of Health and Human Services, Office of Child Support Services (OCSS). Under this matching program, OCSS will provide SSA with quarterly wage (QW) and unemployment insurance (UI) information located in the National Directory of New Hires (NDNH) to allow SSA to determine eligibility of applicants for Extra Help (low-income subsidy assistance) under the Medicare Prescription Drug, Improvement, and Modernization Act (MMA) of 2003. This agreement assists SSA in determining eligibility of applicants for Extra Help, redetermining eligibility of existing Extra Help beneficiaries during periodic screening, and administering the Extra Help program.

Learn More
Notice 11 Apr 2025 regulations, healthcare, privacy act, social security, irs, compliance

🏥SSA Announces New Matching Program with IRS for Medicare Benefits

In accordance with the provisions of the Privacy Act, as amended, this notice announces a new matching program with the United States Department of the Treasury, Internal Revenue Service (IRS). Under this matching program, the IRS will disclose IRS to SSA certain return information for the purpose of verifying eligibility for the Medicare Part D Low Income Subsidy (LIS) and determines the correct subsidy percentage of benefits provided under the Social Security Act (Act).

Learn More
Notice 9 Apr 2025 pharmaceuticals, drug regulations, fda, compliance, healthcare, market withdrawal

🚫FDA Withdraws Approval for 18 New Drug Applications

The Food and Drug Administration (FDA or Agency) is withdrawing approval of 18 new drug applications (NDAs) from multiple applicants. The applicants notified the Agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn.

Learn More
Notice 9 Apr 2025 nih, advisory council, policy discussion, public meeting, research, healthcare

🩺Notice of National Heart, Lung, and Blood Advisory Council Meeting

The Department of Health and Human Services announces a virtual meeting for the National Heart, Lung, and Blood Advisory Council. It aims to discuss program policies and issues that impact heart, lung, and blood health. The meeting is open to public attendance, with options for oral comments and presentations by interested individuals or organizations.

Learn More
Presidential Document 9 Apr 2025 regulation, government initiatives, medical innovation, cancer control, healthcare

🎗️Implications of Cancer Control Month 2025 for Business Owners

The proclamation for Cancer Control Month 2025 highlights the government's dedication to combating cancer through innovative research and healthcare reforms. It encourages public action to promote health and underscores the importance of preventative measures. The initiative aims to bolster healthcare infrastructure and innovation, improving treatment options for cancer patients.

Learn More
Notice 9 Apr 2025 generic drugs, pharmaceuticals, fda, drug approval, flumadine, healthcare

💊FDA Confirms FLUMADINE Not Withdrawn for Safety or Effectiveness

The Food and Drug Administration (FDA, the Agency, or we) has determined that FLUMADINE (rimantadine hydrochloride) tablet, 100 milligrams (mg), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

Learn More
Notice 9 Apr 2025 regulations, andas, fda, drug approval, pharmaceutical, healthcare

💊FDA Finds VIBRAMYCIN Not Withdrawn, Impacts Generic Drug Market

The Food and Drug Administration (FDA, Agency, or we) has determined that VIBRAMYCIN (doxycycline) for oral suspension, equivalent (EQ) 25 milligrams (mg) base/5 milliliters (mL), was not withdrawn from sale for reasons of safety or effectiveness. This determination means that FDA will not begin procedures to withdraw approval of abbreviated new drug applications (ANDAs) that refer to this drug product, and it will allow FDA to continue to approve ANDAs that refer to the product as long as they meet relevant legal and regulatory requirements.

Learn More
Presidential Document 9 Apr 2025 national events, social responsibility, public awareness, healthcare, organ donation

❤️Proclamation for National Donate Life Month

This proclamation honors National Donate Life Month, recognizing the compassion of organ donors. It highlights the critical need for more registered donors and acknowledges the impact of donations on lives. The President urges Americans to consider signing up to be organ donors, emphasizing the life-saving potential of this selfless act.

Learn More
Notice 4 Apr 2025 compliance, healthcare, grants, nih, infectious diseases, contract proposals

🏥NIH Notice of Closed Meeting on NTM Infections Review

The Department of Health and Human Services announces a closed meeting by the National Institute of Allergy and Infectious Diseases to evaluate contract proposals for developing medical interventions targeting Non-Tuberculosis Mycobacterial infections. The meeting will discuss confidential matters and will take place via video assistance. Contact information for inquiries is provided.

Learn More